explore -WSS

explore

author：comprehensive 2025-10-04 06:39:22 - browse：23914

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： STAT series 'Denied by AI' wins major journalism prizes

hotspot

WSS

Abbott's new stent may help patients with peripheral artery disease

Psychedelics group wrestles with new pharma identity

As demand for Covid shots wanes, Moderna seeks its next success

WuXi Biologics beefs up its lobbying operation

Activists slam private health insurers over coverage restrictions

Ripples from Flovent's discontinuation is killing children with asthma

leisure time

explore

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Malaria cases in Florida and Texas: Here’s what you need to know

Fertility clinic egg and embryo storage is a disaster

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

New air purifier tech could be key to improving indoor air quality

Medical leaders decry Supreme Court decision on affirmative action

Duchenne breakthrough therapy leaves behind pioneering families

Duchenne breakthrough therapy leaves behind pioneering families

FDA approval of Sarepta Duchenne genetic therapy gives me hope

focus

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Anesthesiologist group: stop taking Ozempic before surgery

Oak Street deal isn't the answer to health care's woes

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

leisure time

hotspot

hotspot

explore